Evidence map›Paper›PMID 24188705›Full record

ReviewAntiviral research2013

Rectal pre-exposure prophylaxis (PrEP).

Lisa C Rohan, Haitao Yang, Lin Wang

Abstract readReview
In one paragraph

Review in Antiviral research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. On-demand microbicide products: design matters.Drug delivery and translational research · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lisa C RohanDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States; Magee-Womens Research Institute, Pittsburgh, PA, United States. Electronic address: rohanlc@upmc.edu.
Haitao Yang
Lin Wang
Magee-Womens Research Institute · US

Funding

Topical Antiretrovirals to Prevent Rectal HIV InfectionU19AI082637 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI GABELNICK, HENRY L · 2009 to 2013
$11.1M
NIAID NIH HHS AI082637NIAID NIH HHS U19 AI082637
6 · The paper itself

Abstract

Rectal pre-exposure prophylaxis (PrEP) will be a critical component of HIV prevention products due to the prevalence of unprotected receptive anal intercourse among men who have sex with men and heterosexual couples. Given the biological considerations of this compartment and the complexity of HIV infection, design of a successful rectal microbicide product faces a number of challenges. Important information is being compiled to begin to address deficits in knowledge toward design of rectal PrEP products for men and women. Aspects of formulation development and preclinical and clinical evaluation of rectal products studied to date are summarized in this review. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies," held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research.

Indexed as

Administration, RectalAnti-Retroviral AgentsFemaleHIV-1HIV InfectionsHomosexuality, MaleHumansMaleSexual BehaviorAnti-Retroviral AgentsHIV preventionMicrobicidesRectal pre-exposure prophylaxis

Identifiers

PMID24188705
PMCPMC3896093
OpenAlexW2033523263

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.